CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4

Cell Death and Disease

Volumn 6, Issue 1, 2015, Pages

  Wang, L ^a   Zhou, H ^b   Wang, Y ^c   Cui, G ^c,d   Di, L J ^a  

^a University of Macau   (Macao)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c University of Macau   (Macao)

^d ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; BINDING PROTEIN; C TERMINAL BINDING PROTEIN; GLUCOSE; GLUTAMATE DEHYDROGENASE; GLUTAMINE; SIRTUIN 4; UNCLASSIFIED DRUG; 2-KETO-4-METHYLTHIOBUTYRIC ACID; ALCOHOL DEHYDROGENASE; C-TERMINAL BINDING PROTEIN; DNA BINDING PROTEIN; METHIONINE; MITOCHONDRIAL PROTEIN; SIRT4 PROTEIN, HUMAN; SIRTUIN;

ACIDIFICATION; AMINO ACID METABOLISM; AMMONIA FORMATION; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GRAFT; CANCER GROWTH; CELL PH; CELL SURVIVAL; CITRIC ACID CYCLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE EXPRESSION REGULATION; GENE LOSS; GENE REPRESSION; GLUTAMINOLYSIS; GLYCOLYSIS; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PH HOMEOSTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPRESSOR GENE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL RESPIRATION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; PH; TUMOR CELL LINE;

ALCOHOL OXIDOREDUCTASES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL RESPIRATION; DNA-BINDING PROTEINS; GLUTAMINE; GLYCOLYSIS; HOMEOSTASIS; HUMANS; HYDROGEN-ION CONCENTRATION; METHIONINE; MICE; MICE, NUDE; MITOCHONDRIAL PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; SIRTUINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927626428     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.587     Document Type: Article

References (48)

1. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2012; 2: 881-898.
2. Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab 2011; 14: 443-451.
3. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011; 27: 441-464.
4. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-1344.
5. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
6. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-19350.
7. Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell typespecific glutamine independence in breast epithelia. PLoS Genet 2011; 7: e1002229.
8. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
9. Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci Signal 2010; 3: ra31.
10. SeltzerMJ, Bennett BD, Joshi AD,Gao P, Thomas AG, Ferraris DV et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70: 8981-8987.
11. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18: 207-219.
12. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010; 35: 427-433.
13. Shanware NP, Mullen AR, DeBerardinis RJ, Abraham RT. Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med 2011; 89: 229-236.
14. Hildebrand JD, Soriano P. Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development. Mol Cell Biol 2002; 22: 5296-5307.
15. Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F et al. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 2003; 422: 735-738.
16. Zhao LJ, Subramanian T, Vijayalingam S, Chinnadurai G. PLDLS-dependent interaction of E1A with CtBP: regulation of CtBP nuclear localization and transcriptional functions. Oncogene 2007; 26: 7544-7551.
17. Byun JS, Gardner K. C-terminal binding protein: a molecular link between metabolic imbalance and epigenetic regulation in breast cancer. Int J Cell Biol 2013; 2013: 647975.
18. Byun JS, Gardner K. Wounds that will not heal: pervasive cellular reprogramming in cancer. Am J Pathol 2013; 182: 1055-1064.
19. Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S et al. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun 2013; 4: 1449.
20. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell 2009; 36: 469-476.
21. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414.
22. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
23. Jeong SM, Lee A, Lee J, Haigis MC. SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma. J Biol Chem 2014; 289: 4135-4144.
24. Zhdanov AV, Waters AH, Golubeva AV, Dmitriev RI, Papkovsky DB. Availability of the key metabolic substrates dictates the respiratory response of cancer cells to the mitochondrial uncoupling. Biochim Biophys Acta 2014; 1837: 51-62.
25. Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013; 153: 840-854.
26. Jeong SM, Xiao C, Finley LW, Lahusen T, Souza AL, Pierce K et al. SIRT4 has tumorsuppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 2013; 23: 450-463.
27. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J et al. Glucose-independent glutamine metabolismvia TCA cycling for proliferation and survival in B cells. Cell Metab 2012; 15: 110-121.
28. Lu P, Ma D, Chen Y, Guo Y, Chen GQ, Deng H et al. L-glutamine provides acid resistance for Escherichia coli through enzymatic release of ammonia. Cell Res 2013; 23: 635-644.
29. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006; 126: 941-954.
30. Consortium EP, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74.
31. Santo-Domingo J, Demaurex N. Perspectives on: SGP symposium on mitochondrial physiology and medicine: the renaissance of mitochondrial pH. J Gen Physiol 2012; 139: 415-423.
32. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010; 107: 8788-8793.
33. Straza MW, Paliwal S, Kovi RC, Rajeshkumar B, Trenh P, Parker D et al. Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle 2010; 9: 3740-3750.
34. Hilbert BJ, Grossman SR, Schiffer CA, Royer WE Jr. Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design. FEBS Lett 2014; 588: 1743-1748.
35. Barry MA, Eastman A. Endonuclease activation during apoptosis: the role of cytosolic Ca2+ and pH. Biochem Biophys Res Commmun 1992; 186: 782-789.
36. Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. Nat Rev Mol Cell Biol 2010; 11: 50-61.
37. McBrian MA, Behbahan IS, Ferrari R, Su T, Huang TW, Li K et al. Histone acetylation regulates intracellular pH. Mol Cell 2013; 49: 310-321.
38. Tamarappoo BK, Joshi S, Welbourne TC. Interorgan glutamine flow regulation in metabolic acidosis. Miner Electrolyte Metab 1990; 16: 322-330.
39. Fjeld CC, Birdsong WT, Goodman RH. Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA 2003; 100: 9202-9207.
40. Zhang Q, Wang SY, Fleuriel C, Leprince D, Rocheleau JV, Piston DW et al. Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex. Proc Natl Acad Sci USA 2007; 104: 829-833.
41. Kajimura S, Seale P, Tomaru T, Erdjument-Bromage H, Cooper MP, Ruas JL et al. Regulation of the brown and white fat gene programs through a PRDM16/CtBP transcriptional complex. Genes Dev 2008; 22: 1397-1409.
42. Di LJ, Fernandez AG, De Siervi A, Longo DL, Gardner K. Transcriptional regulation of BRCA1 expression by a metabolic switch. Nat Struct Mol Biol 2010; 17: 1406-1413.
43. Jack BH, Pearson RC, Crossley M. C-terminal binding protein: a metabolic sensor implicated in regulating adipogenesis. Int J Biochem Cell Biol 2011; 43: 693-696.
44. Siles L, Sanchez-Tillo E, Lim JW, Darling DS, Kroll KL, Postigo A. ZEB1 imposes a temporary stage-dependent inhibition of muscle gene expression and differentiation via CtBP-mediated transcriptional repression. Mol Cell Biol 2013; 33: 1368-1382.
45. Jack BH, Crossley M. GATA proteins work together with friend of GATA (FOG) and C-terminal binding protein (CTBP) co-regulators to control adipogenesis. J Biol Chem 2010; 285: 32405-32414.
46. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. Jo Cell Biol 2007; 178: 93-105.
47. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013; 496: 101-105.
48. Wang L, Teng R, Di L, Rogers H, Wu H, Kopp JB et al. PPARalpha and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. Diabetes 2013; 62: 4122-4131.